The beta thalassemias are characterized by a deficiency of adult (beta) globin chains of adult hemoglobin (Hb), an excess of toxic, unmatched alpha globin chains, and intramedullary hemolysis. The resulting anemia develops only after fetal (gamma) globin synthesis and Hb F is suppressed in infancy. Induction of fetal (gamma) globin to levels which improve globin chain balance by even 10 percent can prolong red blood cell survival and diminish clinical morbidity. 5-Azacytidine has increased hemoglobin (Hb) levels by 1.8-3 gmd/d1 in thalassemia, but also causes general cytopenias and carries carcinogenicity risks. Fatty acids induce (gamma) globin experimentally. Arginine Butyrate, a prototype fatty acid, has been most effective when given intermittently or Pulsed, inducing Hb F to a mean level of 22 percent in 7/9 adults with sickle cell disease and increasing total hemoglobin by 3 gm/dl over baseline levels in 5/6 beta thalassemia patients. Two clinical pilot studies are proposed to test the hypotheses that therapy with Pulsed Butyrate, or rhu-EP0 + Pulsed Butyrate, will induce gamma globin chain synthesis sufficiently to improve non alpha: alpha globin chain balance and red blood cell survival, and increase total Hb in a significant proportion of patients with beta thalassemia intermedia. Baseline hematologic levels will be assayed four times over a two-month period. Butyrate will then be administered during an Induction Phase, to determine a patient's optimal dose, followed by a """"""""Maintenance Phase"""""""" of therapy for 3 months. Pulsed Butyrate will also be tested with rhu-EPO. The proportions of patients on each study in whom the following endpoints are achieved, compared to baseline levels, will be analyzed: 1) an increase in total Hb of at least 2.0 grams/dl, 2) an increase in hematocrit of at least 5 percent, 3) a decrease in hemolysis, measured by LDH and bilirubin, 4) improvement in globin chain synthesis by 10 percent. Whether specific genotypes and in vitro response to Butyrate correlate with clinical responses will also be analyzed. These studies should determine the proportion and some genotypes of beta thalassemia patients which can benefit from Pulsed Butyrate plus/minus rhu-EP0 therapy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL061208-03
Application #
6185012
Study Section
Special Emphasis Panel (ZHL1-CSR-K (M1))
Program Officer
Badman, David G
Project Start
1998-09-30
Project End
2003-07-31
Budget Start
2000-08-01
Budget End
2001-07-31
Support Year
3
Fiscal Year
2000
Total Cost
$433,583
Indirect Cost
Name
Boston University
Department
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Perrine, Susan P; Castaneda, Serguei A; Chui, David H K et al. (2010) Fetal globin gene inducers: novel agents and new potential. Ann N Y Acad Sci 1202:158-64
Perrine, Susan P (2008) Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr Ann 37:339-46
Weinberg, Rona S; Ji, Xinjun; Sutton, Millicent et al. (2005) Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 105:1807-9
Castaneda, Serguei; Boosalis, Michael S; Emery, David et al. (2005) Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis 35:217-26
Perrine, Susan P; Castaneda, Serguei A; Boosalis, Michael S et al. (2005) Induction of fetal globin in beta-thalassemia: Cellular obstacles and molecular progress. Ann N Y Acad Sci 1054:257-65
McGovern, Margaret M; Wasserstein, Melissa P; Aron, Alan et al. (2003) Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy. J Pediatr 142:709-13
Pace, Betty S; White, Gary L; Dover, George J et al. (2002) Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 100:4640-8
Boosalis, M S; Bandyopadhyay, R; Bresnick, E H et al. (2001) Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood 97:3259-67